ABSI צמיחת רווחי EPS רבעונית Absci
Quarterly growth in net income per share demonstrates the synergy between cloud AI and physical synthetic biology laboratories at Absci (ABSI). The business's sustainability is driven by computer modeling, which reduces the volume of chemical waste. The 12.10 mark characterizes this parameter, highlighting the potential for data monetization through long-term contracts with pharmaceutical behemoths for antibody creation.
%20%D7%A9%D7%99%D7%A0%D7%95%D7%99%20%D7%91%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_ABSI_-_Absci_-_Year-over-year-net-earnings-per-share-change-for-the-last-twelve-months "ABSI Absci: צמיחת רווחי EPS רבעונית בטווח 04.07.2022 - 10.11.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור Absci Bio (ABSI)
For Absci (ABSI), the efficiency of its AI platform in antibody creation converts directly into net earnings per share dynamics. This metric measures the quarterly percentage change in EPS, reflecting the monetization speed of licensing agreements. By analyzing the quarterly EPS growth rate, an investor assesses the business model's resilience to market volatility. A steady upward trend confirms the scalability of digital developments, while sharp deviations signal increased fundamental risks.
